-
Interpretation of “Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma”
On December 9-10, 2023, the “Huaxia Shanghai Liver Disease Forum and Shanghai Liver Disease Summit” was successfully held, sponsored by the Huaxia Liver Disease Association, organized by the Shanghai “Liver” Magazine, and co-organized by the Shanghai Medical Association Hepatology Subspecialty Branch, Shanghai Physicians Association Infectious Disease Physicians Branch, Shanghai Infectious Disease Clinical Quality Control Center,…
-
Potentially Underestimated! Recent Advances in Screening, Treatment, and Prevention of HBV Combined with HDV Infection
Hepatitis D virus (HDV) is a defective virus that relies on hepatitis B virus (HBV) to produce infectious particles for transmission. The combined infection of both is considered one of the most severe forms of chronic viral hepatitis, posing a significant threat to human health. At the 9th “Silk Road Hepatitis Forum,” Dr. Xiaozhong Wang,…
-
Unresolved Issues in Pediatric Hepatitis B Treatment Guidelines
China is a high-incidence country for hepatitis B virus (HBV), with mother-to-child transmission being a significant route of HBV infection in children. If infected with HBV, 15% to 25% of children may develop into chronic carriers, posing risks of liver cirrhosis and liver cancer. Therefore, understanding the epidemiological characteristics of the disease and taking timely…
-
Lymphoma Research and New Drug Exploration in the Era of Big Data in China | UCLI-ICML Joint Session
Editor’s Note: From June 13-17, 2023, the biennial International Conference on Malignant Lymphoma (ICML), the largest global event in the field, took place in the picturesque town of Lugano, Switzerland.…
-
Discovery and Verification of HBV Auxiliary Receptor NRP1
Hepatitis B Virus (HBV) infection is one of the main causes of liver diseases, affecting approximately 292 million people worldwide who are chronic carriers of HBV, leading to severe conditions like liver cirrhosis and primary liver cancer. The infection process of HBV relies on the binding of the viral envelope proteins to receptors on the…
-
Dr. Alexander Fosså：Phase II waveLINE-004 Study of ROR1-ADC Treatment for R/R DLBCL
On the 17th International Conference on Malignant Lymphoma (ICML), Dr. Alexander Fosså from Oslo University Hospital presented the results of the Zilovertamab vedotin (MK-2140) treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), a Phase II open-label, waveLINE-004 study. Oncology Frontier interviewed Dr. Fosså at the conference.
-
Dr. Franco Cavalli: Highlights of ICML 2023 & the Emerging Significance of China in Lymphoma Research
From June 13-17, 2023, the biennial international lymphoma academic event – the 17th International Conference on Malignant Lymphoma (ICML) was held in Lugano. As the world’s largest international conference on malignant lymphoma, ICML attracts widespread attention from lymphoma experts and scholars both domestically and abroad. In our interview with the conference chair, Dr. Franco Cavalli,…
-
Dr. Huiqiang Huang: Combining PD-1 Monoclonal Antibody and HDAC Inhibitor with Conventional P-Gemox Significantly Improves the Treatment Outcome for NK/T Cell Lymphoma
Editor’s Note: From June 17th to 23rd, 2023, the 17th International Conference on Malignant Lymphoma (ICML) was held grandly in Lugano, Switzerland. As the world’s largest conference on malignant lymphoma,…
Connecting Medical Expertise through Media